UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Apr

    03

    UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

    Mar

    31

    The First UCB US Rare Disease Connect in Neurology (RDCN) Annual Summit Launches at American Academy of Neurology 2025

    Mar

    28

    Join UCB at the MGFA National Patient Conference and Visit Our Experience Room

    Mar

    27

    UCB’s Kassandra Watson and Windy Wang Recognized by Healthcare Businesswomen’s Association (HBA) as Luminary and Rising Star

    Mar

    19

    New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

    Mar

    12

    Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

    Mar

    07

    Improving Dermatology Outcomes with Timely Diagnosis and Long-Lasting Treatment Options

    Mar

    07

    BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

    Mar

    07

    BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

    Mar

    05

    Voices on Value: Prioritizing Patients Now and Into the Future